Topics

First Patient Dosed with Cellectis' New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

16:34 EST 15 Jan 2020 | FinanzNachrichten

AMELI-01 Clinical Trial Uses New UCART123 Construct With Optimized Production Process New IND Number First Patient Dosed at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASD...

Original Article: First Patient Dosed with Cellectis' New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

NEXT ARTICLE

More From BioPortfolio on "First Patient Dosed with Cellectis' New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...